We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-5.92%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$19.2M
Cap. Flow
+$80.6M
Cap. Flow %
16.65%
Top 10 Hldgs %
73.12%
Holding
59
New
4
Increased
1
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$76.1M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$6.17M
3
ATYR
aTyr Pharma
ATYR
+$3.83M
4
INZY
Inozyme Pharma
INZY
+$1.33M
5
CYPH
Cypherpunk Technologies Inc
CYPH
+$444K

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.65M
2
ALBO
Albireo Pharma Inc
ALBO
+$2.16M
3
ACLX
Arcellx
ACLX
+$1.45M
4
SWTX
SpringWorks Therapeutics
SWTX
+$578K
5
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$195K

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
26
Immatics
IMTX
$1.32B
$3.42M 0.71%
495,000
– –
INZY
27
DELISTED
Inozyme Pharma
INZY
$2.89M 0.6%
+504,407
New +$1.33M
DAWN
28
DELISTED
Day One Biopharmaceuticals
DAWN
$2.63M 0.54%
196,425
– –
TNGX icon
29
Tango Therapeutics
TNGX
$4.41B
$2.49M 0.51%
630,000
– –
DBTX
30
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$2.42M 0.5%
801,629
– –
TERN
31
DELISTED
Terns Pharmaceuticals
TERN
$2.4M 0.5%
202,348
– –
SYRS
32
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.35M 0.49%
881,450
– –
IGMS
33
DELISTED
IGM Biosciences
IGMS
$2.13M 0.44%
154,664
– –
IOBT
34
DELISTED
IO Biotech
IOBT
$1.89M 0.39%
1,008,437
– –
ELEV
35
DELISTED
Elevation Oncology
ELEV
$1.58M 0.33%
830,565
– –
BOLT icon
36
Bolt Biotherapeutics
BOLT
$7.78M
$1.46M 0.3%
52,458
– –
EYPT icon
37
EyePoint Inc
EYPT
$1.2B
$1.41M 0.29%
480,000
– –
VTVT icon
38
vTv Therapeutics
VTVT
$139M
$1.32M 0.27%
40,888
– –
ALXO icon
39
ALX Oncology
ALXO
$290M
$1.19M 0.25%
262,786
– –
TIL icon
40
Instil Bio
TIL
$50.3M
$1.18M 0.24%
89,414
– –
VIRX
41
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.1M 0.23%
689,709
– –
ALLK
42
DELISTED
Allakos
ALLK
$766K 0.16%
172,089
– –
EQ icon
43
Equillium
EQ
$133M
$449K 0.09%
615,541
– –
ATXS
44
DELISTED
Astria Therapeutics
ATXS
$333K 0.07%
25,000
– –
KLRS
45
Kalaris Therapeutics
KLRS
$96.8M
$324K 0.07%
3,580
– –
BCEL
46
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$300K 0.06%
262,827
-134,008
-34% -$195K
CYPH
47
Cypherpunk Technologies Inc
CYPH
$73.3M
$288K 0.06%
+84,604
New +$444K
SYRE icon
48
Spyre Therapeutics
SYRE
$9.25B
$256K 0.05%
35,349
– –
SNCE
49
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$253K 0.05%
45,000
– –
KALA icon
50
KALA BIO
KALA
$14.5M
$181K 0.04%
240
– –
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q1 2023 Portfolio in Review

As of Q1 2023, Samsara BioCapital held 59 positions worth $484M, up 4.1% from $465M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Samsara BioCapital deployed $80.6M of net new capital in Q1 2023, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Mineralys Therapeutics: 4,519,361 shares worth $70.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $2.65M trimmed.

  • Samsara BioCapital's largest Q1 2023 buy was Mineralys Therapeutics: 4,519,361 shares worth $70.8M.
  • Samsara BioCapital added most to Avadel Pharmaceuticals in Q1 2023, an estimated $6.17M increase.
  • Samsara BioCapital's biggest Q1 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $2.65M.
  • Samsara BioCapital fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $2.16M.
  • Samsara BioCapital's ten largest holdings make up 73% of its $484M portfolio in Q1 2023.
  • Samsara BioCapital opened 4 new positions and closed 3 in Q1 2023.
  • Samsara BioCapital's portfolio value rose 4.1% quarter-over-quarter to $484M.

Based on Samsara BioCapital's 13F filing for Q1 2023, filed 15 May 2023.